In addition, the single blockade of the TIGIT receptor resulted in an increased NK cell-mediated killing of AML cells that can be further augmented by targeting of the purinergic pathway via a combinatorial blockade of TIGIT together with CD39 or A2AR. The gene discussed is TIGIT; the disease is acute myeloid leukemia.